BIOMAT Database Logo BIOMAT Database Logo

Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitors. 2013

Hong-Tao Xu, and Susan P Colby-Germinario, and Wei Huang, and Maureen Oliveira, and Yingshan Han, and Yudong Quan, and Christos J Petropoulos, and Mark A Wainberg
McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada.

Resistance to the recently approved nonnucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine (RPV) commonly involves substitutions at positions E138K and K101E in HIV-1 reverse transcriptase (RT), together with an M184I substitution that is associated with resistance to coutilized emtricitabine (FTC). Previous biochemical and virological studies have shown that compensatory interactions between substitutions E138K and M184I can restore enzyme processivity and the viral replication capacity. Structural modeling studies have also shown that disruption of the salt bridge between K101 and E138 can affect RPV binding. The current study was designed to investigate the impact of K101E, alone or in combination with E138K and/or M184I, on drug susceptibility, viral replication capacity, and enzyme function. We show here that K101E can be selected in cell culture by the NNRTIs etravirine (ETR), efavirenz (EFV), and dapivirine (DPV) as well as by RPV. Recombinant RT enzymes and viruses containing K101E, but not E138K, were highly resistant to nevirapine (NVP) and delavirdine (DLV) as well as ETR and RPV, but not EFV. The addition of K101E to E138K slightly enhanced ETR and RPV resistance compared to that obtained with E138K alone but restored susceptibility to NVP and DLV. The K101E substitution can compensate for deficits in viral replication capacity and enzyme processivity associated with M184I, while M184I can compensate for the diminished efficiency of DNA polymerization associated with K101E. The coexistence of K101E and E138K does not impair either viral replication or enzyme fitness. We conclude that K101E can play a significant role in resistance to RPV.

UI MeSH Term Description Entries
D007963 Leukocytes, Mononuclear Mature LYMPHOCYTES and MONOCYTES transported by the blood to the body's extravascular space. They are morphologically distinguishable from mature granulocytic leukocytes by their large, non-lobed nuclei and lack of coarse, heavily stained cytoplasmic granules. Mononuclear Leukocyte,Mononuclear Leukocytes,PBMC Peripheral Blood Mononuclear Cells,Peripheral Blood Human Mononuclear Cells,Peripheral Blood Mononuclear Cell,Peripheral Blood Mononuclear Cells,Leukocyte, Mononuclear
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D009570 Nitriles Organic compounds containing the -CN radical. The concept is distinguished from CYANIDES, which denotes inorganic salts of HYDROGEN CYANIDE. Nitrile
D011724 Pyridazines Six-membered rings with two adjacent nitrogen atoms also called 1,2-diazine.
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D003521 Cyclopropanes Three-carbon cycloparaffin cyclopropane (the structural formula (CH2)3) and its derivatives.
D003841 Deoxycytidine A nucleoside component of DNA composed of CYTOSINE and DEOXYRIBOSE. Cytosine Deoxyribonucleoside,Cytosine Deoxyriboside,Deoxyribonucleoside, Cytosine,Deoxyriboside, Cytosine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068679 Emtricitabine A deoxycytidine analog and REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B viruses. It is used to treat HIV INFECTIONS. Beta-L-2',3'-dideoxy-5-fluoro-3'-thiacytidine,Coviracil,Emtriva,Beta L 2',3' dideoxy 5 fluoro 3' thiacytidine
D000068696 Rilpivirine A diarylpyrimidine derivative and REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 that is used in the treatment of HIV INFECTIONS. It is also used in combination with other ANTI-HIV AGENTS, since ANTIVIRAL DRUG RESISTANCE emerges rapidly when it is used alone. R278474,Rilpivirine HCl,Rilpivirine Hydrochloride,TMC 278,TMC-278,TMC278,278, TMC,HCl, Rilpivirine,Hydrochloride, Rilpivirine

Related Publications

Hong-Tao Xu, and Susan P Colby-Germinario, and Wei Huang, and Maureen Oliveira, and Yingshan Han, and Yudong Quan, and Christos J Petropoulos, and Mark A Wainberg
HIV-1 reverse transcriptase resistance to nonnucleoside inhibitors.
January 1996, Biochemistry,
Hong-Tao Xu, and Susan P Colby-Germinario, and Wei Huang, and Maureen Oliveira, and Yingshan Han, and Yudong Quan, and Christos J Petropoulos, and Mark A Wainberg
The genetic and functional basis of HIV-1 resistance to nonnucleoside reverse transcriptase inhibitors.
January 1994, Archives of virology. Supplementum,
Hong-Tao Xu, and Susan P Colby-Germinario, and Wei Huang, and Maureen Oliveira, and Yingshan Han, and Yudong Quan, and Christos J Petropoulos, and Mark A Wainberg
The emerging profile of cross-resistance among the nonnucleoside HIV-1 reverse transcriptase inhibitors.
July 2014, Viruses,
Hong-Tao Xu, and Susan P Colby-Germinario, and Wei Huang, and Maureen Oliveira, and Yingshan Han, and Yudong Quan, and Christos J Petropoulos, and Mark A Wainberg
Development of nonnucleoside HIV reverse transcriptase inhibitors.
January 1996, Methods in enzymology,
Hong-Tao Xu, and Susan P Colby-Germinario, and Wei Huang, and Maureen Oliveira, and Yingshan Han, and Yudong Quan, and Christos J Petropoulos, and Mark A Wainberg
Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol.
November 2006, PLoS pathogens,
Hong-Tao Xu, and Susan P Colby-Germinario, and Wei Huang, and Maureen Oliveira, and Yingshan Han, and Yudong Quan, and Christos J Petropoulos, and Mark A Wainberg
Minority variants associated with resistance to HIV-1 nonnucleoside reverse transcriptase inhibitors during primary infection.
October 2012, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology,
Hong-Tao Xu, and Susan P Colby-Germinario, and Wei Huang, and Maureen Oliveira, and Yingshan Han, and Yudong Quan, and Christos J Petropoulos, and Mark A Wainberg
Functional analysis of HIV-1 reverse transcriptase amino acids involved in resistance to multiple nonnucleoside inhibitors.
September 1992, The Journal of biological chemistry,
Hong-Tao Xu, and Susan P Colby-Germinario, and Wei Huang, and Maureen Oliveira, and Yingshan Han, and Yudong Quan, and Christos J Petropoulos, and Mark A Wainberg
Developing novel nonnucleoside HIV-1 reverse transcriptase inhibitors: beyond the butterfly.
January 2006, Current pharmaceutical design,
Hong-Tao Xu, and Susan P Colby-Germinario, and Wei Huang, and Maureen Oliveira, and Yingshan Han, and Yudong Quan, and Christos J Petropoulos, and Mark A Wainberg
Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase.
June 2001, Proceedings of the National Academy of Sciences of the United States of America,
Hong-Tao Xu, and Susan P Colby-Germinario, and Wei Huang, and Maureen Oliveira, and Yingshan Han, and Yudong Quan, and Christos J Petropoulos, and Mark A Wainberg
Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors.
November 2009, Journal of acquired immune deficiency syndromes (1999),
Copied contents to your clipboard!